Cantor Fitzgerald Analyzes Verve Therapeutics' FY2025 Earnings

On January 21, 2025, Cantor Fitzgerald issued its financial projections for Verve Therapeutics, Inc. (NASDAQ:VERV). Analyst R. Bienkowski anticipates that Verve will report an earnings per share (EPS) of ($2.67) for the fiscal year 2025. This forecast is slightly below the current consensus estimate, which stands at ($2.49) per share for the year.

In its recent quarterly earnings report released on November 5, 2024, Verve Therapeutics demonstrated a better-than-expected performance. The company reported an EPS of ($0.59), exceeding the analysts' consensus prediction of ($0.70) by $0.11. During this quarter, Verve generated revenue of $6.87 million, outperforming expectations that had anticipated only $2.75 million in sales. Over the past year, Verve Therapeutics experienced substantial growth, with its quarterly revenue soaring by 120.2% compared to the same period the previous year, although it still recorded a negative return on equity of 35.23% and a negative net margin of 807.65%.

Following the earnings report, several other investment firms commented on Verve. On November 6, 2024, Royal Bank of Canada adjusted its price target for Verve's shares, reducing it from $20.00 to $17.00, while maintaining an “outperform” rating. Similarly, HC Wainwright decreased its price target from $15.00 to $14.00 and rated the stock as a “buy.” Furthermore, Canaccord Genuity Group raised its price objective for Verve's shares significantly from $29.00 to $32.00, aligning it with a “buy” rating.

Current Stock Performance

As of January 23, 2025, shares of Verve Therapeutics (NASDAQ:VERV) opened at $7.80. The company's stock has shown recent volatility, marked by a 50-day simple moving average of $5.84 and a 200-day simple moving average of $5.79. Currently, Verve has a market capitalization of approximately $660.35 million and a negative price-to-earnings (PE) ratio of -3.17, indicating ongoing challenges in profitability. Over the past year, the stock reached a low of $4.30 and a high of $19.34.

Investors' Interest in Verve Therapeutics

Institutional investors have shown notable activity in Verve Therapeutics' stock. Recently, GAMMA Investing LLC increased its stake in the company by an impressive 189.7% during the fourth quarter, now holding 6,054 shares valued at around $34,000 after acquiring an additional 3,964 shares. Other institutional investors, such as Creative Planning and PFG Investments LLC, also purchased new positions in Verve during the third quarter, indicating strong interest in the company. Overall, institutional investors own approximately 97.11% of Verve Therapeutics' shares, reflecting significant institutional confidence.

About Verve Therapeutics

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company focused on developing gene editing therapies aimed at treating cardiovascular diseases in the United States. The firm’s leading candidates include VERVE-101, which aims to permanently disable the PCSK9 gene in the liver, and VERVE-102, targeting the same gene for treating heterozygous familial hypercholesterolemia (HeFH).

Earnings, Stocks, Analysis